Organogenesis Holdings Inc. (ORGO)
| Market Cap | 299.81M -26.8% |
| Revenue (ttm) | 514.70M +12.2% |
| Net Income | -14.55M |
| EPS | -0.12 |
| Shares Out | 128.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 809,425 |
| Open | 2.250 |
| Previous Close | 2.240 |
| Day's Range | 2.210 - 2.365 |
| 52-Week Range | 2.040 - 7.077 |
| Beta | 1.31 |
| Analysts | Buy |
| Price Target | 3.00 (+28.76%) |
| Earnings Date | May 7, 2026 |
About ORGO
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ORGO stock is "Buy." The 12-month stock price target is $3.0, which is an increase of 28.76% from the latest price.
News
Organogenesis initiated with a Hold at Truist
Truist initiated coverage of Organogenesis (ORGO) with a Hold rating and $3 price target Reimbursement changes are driving structural shifts across care settings in 2026 and a shakeout in the…
Organogenesis downgraded to Neutral from Buy at BTIG
BTIG downgraded Organogenesis (ORGO) to Neutral from Buy without a price target following the Q1 report. The company’s Advanced Wound Care recovery is taking longer to play out with limited…
Organogenesis Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw a 58% revenue decline, mainly from advanced wound care, due to CMS policy changes and market disruption. Despite this, market share improved, restructuring was implemented, and key regulatory milestones were achieved. Sequential recovery and profitability are expected by Q4.
Organogenesis Holdings Earnings release: Q1 2026
Organogenesis Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Organogenesis Holdings Quarterly report: Q1 2026
Organogenesis Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the dev...
Organogenesis Holdings Proxy statement: Proxy filing
Organogenesis Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Organogenesis completes rolling submission of ReNu BLA
Organogenesis (ORGO) announced the completion of a rolling biologics license application, or BLA, submission to the FDA for ReNu, a cryopreserved, amniotic suspension allograft developed for the manag...
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain
Why is Organogenesis Stock (ORGO) Up 20% Today?
Shares in regenerative medicine company Organogenesis ($ORGO) strode 20% higher in pre-market trading today after a successful trial of its foot ulcer treatment. Non-Healing Ulcers The company, which ...
Organogenesis achieves primary endpoint in PuraPly study
The company states: “Organogenesis (ORGO) Holdings announced the completion of a randomized controlled trial evaluating PuraPly(R)AM plus standard of care versus SOC alone in the management of non-hea...
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of p...
Organogenesis announces successful FDA meeting, plans to file BLA for ReNu
Organogenesis (ORGO) announced the successful completion of a planned Type-B meeting with the FDA resulting in confirmation to initiate a rolling Biologics Licenses Application for ReNu planned before...
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the d...
Organogenesis price target lowered to $8 from $9 at BTIG
BTIG lowered the firm’s price target on Organogenesis (ORGO) to $8 from $9 and keeps a Buy rating on the shares. The company reported a blowout quarter, but its FY26…
Organogenesis Holdings Earnings Call Transcript: Q4 2025
Record Q4 and 2025 revenue driven by advanced wound care, but 2026 faces a 25%-38% revenue decline due to CMS policy changes and clinician confusion. Management expects recovery and market share gains in the second half of 2026, supported by new investments and product innovation.
Organogenesis Holdings Earnings release: Q4 2025
Organogenesis Holdings released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Organogenesis Holdings Annual report: Q4 2025
Organogenesis Holdings has published its Q4 2025 annual report on February 26, 2026.
Organogenesis Holdings Annual report: Q4 2025
Organogenesis Holdings has published its Q4 2025 annual report on February 26, 2026.
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the de...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of pr...
Organogenesis initiates rolling submission of BLA to FDA for ReNu
Organogenesis (ORGO) announced the initiation of a rolling submission of a Biologics License Application to the FDA for ReNu, a cryopreserved, amniotic suspension allograft developed for the managemen...
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 Initial modules submitted to FDA under rolling review; final modules expected in the first half ...
Organogenesis plans to file BLA for ReNu before end of December
Organogenesis (ORGO) Holdings announced the successful completion of a planned Type-B meeting with the Food and Drug Administration resulting in confirmation to initiate a rolling Biologics Licenses A...